Captor Therapeutics SA (PL:CTX)
:CTX
Want to see PL:CTX full AI Analyst Report?
Top Page
Captor Therapeutics SA
(CTX)
Select Model
Select Model
Rating:42Neutral
Price Target:
zł35.00
▼(-17.06% Downside)
Action:N/A
Date:09/14/25
The overall stock score of 42 for Captor Therapeutics SA is primarily driven by weak financial performance, with significant revenue declines, deep losses, and cash flow challenges typical of a biotech in development. Valuation concerns due to negative earnings further weigh on the score, while limited technical data provides no clear upside. Investors should approach with caution given the high-risk profile.
Positive Factors
Proprietary Technology Platform
Captor Therapeutics' TPD platform offers a unique approach to drug development, potentially providing a competitive edge in creating novel therapies for oncology and autoimmune diseases.
Negative Factors
Declining Revenue
A significant decline in revenue growth poses a challenge to financial sustainability, impacting the company's ability to fund operations and invest in future growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Technology Platform
Captor Therapeutics' TPD platform offers a unique approach to drug development, potentially providing a competitive edge in creating novel therapies for oncology and autoimmune diseases.
Read all positive factors
Captor Therapeutics SA (CTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł497.47M
Dividend YieldN/A
Average Volume (3M)15.34K
Price to Earnings (P/E)―
Beta (1Y)0.32
Revenue Growth-70.55%
EPS Growth4.43%
CountryPL
Employees105
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-7.62
Shares Outstanding6,353,397
10 Day Avg. Volume10,947
30 Day Avg. Volume15,340
Financial Highlights & Ratios
PEG Ratio1.22
Price to Book (P/B)16.92
Price to Sales (P/S)85.26
P/FCF Ratio-10.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.4
Revenue Forecast (FY)zł57.35M
Captor Therapeutics SA Business Overview & Revenue Model
Company Description
Captor Therapeutics SA (CTX) is a biopharmaceutical company focused on developing innovative therapeutics in the field of oncology and autoimmune diseases. Utilizing its proprietary Targeted Protein Degradation (TPD) platform, the company aims to ...
How the Company Makes Money
Captor Therapeutics generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies, which provide funding for research and development efforts. These partnerships often include upfront payments, milesto...
Captor Therapeutics SA Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
60
Neutral
Cash Flow
30
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.66M | 15.82M | 13.20M | 9.16M | 3.99M |
| Gross Profit | -652.00K | 6.42M | 6.90M | 7.07M | 3.25M |
| EBITDA | -48.84M | -32.93M | -64.76M | -28.22M | -24.41M |
| Net Income | -42.00M | -38.43M | -70.58M | -35.89M | -32.57M |
Balance Sheet | |||||
| Total Assets | 40.02M | 87.50M | 97.29M | 113.00M | 143.54M |
| Cash, Cash Equivalents and Short-Term Investments | 32.11M | 39.26M | 75.70M | 90.89M | 117.94M |
| Total Debt | 3.58M | 5.64M | 3.78M | 6.95M | 8.18M |
| Total Liabilities | 16.54M | 23.02M | 28.07M | 16.68M | 19.34M |
| Stockholders Equity | 23.48M | 64.47M | 69.22M | 96.32M | 124.20M |
Cash Flow | |||||
| Free Cash Flow | -36.53M | -32.06M | -55.21M | -23.84M | -33.59M |
| Operating Cash Flow | -36.32M | -31.64M | -52.20M | -22.95M | -28.47M |
| Investing Cash Flow | -21.14M | 273.00K | 19.93M | -17.63M | -5.11M |
| Financing Cash Flow | 28.92M | -4.84M | 36.94M | -6.33M | 140.88M |
Captor Therapeutics SA Technical Analysis
Neutral
42.20
Price Trends
79.49
Negative
80.39
Negative
64.72
Positive
Market Momentum
-0.58
Positive
46.16
Neutral
51.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:CTX, the sentiment is Neutral. The current price of 42.2 is below the 20-day moving average (MA) of 78.97, below the 50-day MA of 79.49, and below the 200-day MA of 64.72, indicating a neutral trend. The MACD of -0.58 indicates Positive momentum. The RSI at 46.16 is Neutral, neither overbought nor oversold. The STOCH value of 51.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PL:CTX.
Captor Therapeutics SA Peers Comparison
UnderperformOutperform
Sector (51)
PL:CTX
Captor Therapeutics SA
78.30
41.90
115.11%
PL:PUR
Pure Biologics SA
1.92
-1.66
-46.34%
PL:RVU
Ryvu Therapeutics SA
22.65
-10.00
-30.63%
PL:SVE
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
3.00
-2.64
-46.80%
PL:MOC
OncoArendi Therapeutics SA
5.34
-3.01
-36.05%
PL:SLV
Selvita SA
33.30
-1.50
-4.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.